2014
Vandetanib and Indwelling Pleural Catheter for Non–Small-Cell Lung Cancer With Recurrent Malignant Pleural Effusion
Massarelli E, Onn A, Marom EM, Alden CM, Liu DD, Tran HT, Mino B, Wistuba II, Faiz SA, Bashoura L, Eapen GA, Morice RC, Lee J, Hong WK, Herbst RS, Jimenez CA. Vandetanib and Indwelling Pleural Catheter for Non–Small-Cell Lung Cancer With Recurrent Malignant Pleural Effusion. Clinical Lung Cancer 2014, 15: 379-386. PMID: 24913066, PMCID: PMC4160385, DOI: 10.1016/j.cllc.2014.04.002.Peer-Reviewed Original ResearchConceptsRecurrent malignant pleural effusionCell lung cancer patientsMalignant pleural effusionLung cancer patientsCell lung cancerPleural effusionCancer patientsMedian timeCatheter placementLung cancerEastern Cooperative Oncology Group performance statusPoor overall median survivalEnd pointSingle-arm phase II clinical trialPhase II clinical trialIndwelling pleural catheterOverall median survivalPrimary end pointSecondary end pointsDaily oral doseWeeks of treatmentPleural fluid cytologyVEGF receptor inhibitorPleural fluid cytokinesEligible patients
2008
IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative and Therapeutic Modalities)
Hong W, Herbst R. IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative and Therapeutic Modalities). 2008 DOI: 10.21236/ada486510.Peer-Reviewed Original ResearchMalignant pleural effusionRaf/MEK/ERK pathwayMEK/ERK pathwayRas/Raf/MEK/ERK pathwayAdvanced diseasePleural effusionLung cancerNSCLC pathogenesisMolecular therapyEGFR pathwayERK pathwayCD-ROM programSignal transduction pathwaysImaging techniquesPathwayTransduction pathwaysPulmonologistsEffusionPathogenesisTherapyCancerDiseasePreventionReceptorsIMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative and Therapeutic Modalities)
Hong W, Herbst R. IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative and Therapeutic Modalities). 2008 DOI: 10.21236/ada483184.Peer-Reviewed Original ResearchMalignant pleural effusionRaf/MEK/ERK pathwayMEK/ERK pathwayRas/Raf/MEK/ERK pathwayAdvanced diseasePleural effusionLung cancerNSCLC pathogenesisMolecular therapyEGFR pathwayERK pathwayCD-ROM programSignal transduction pathwaysImaging techniquesPathwayTransduction pathwaysPeptide approachPulmonologistsEffusionPathogenesisTherapyCancerDiseasePreventionReceptors
2000
Production of Experimental Malignant Pleural Effusions Is Dependent on Invasion of the Pleura and Expression of Vascular Endothelial Growth Factor/Vascular Permeability Factor by Human Lung Cancer Cells
Yano S, Shinohara H, Herbst R, Kuniyasu H, Bucana C, Ellis L, Fidler I. Production of Experimental Malignant Pleural Effusions Is Dependent on Invasion of the Pleura and Expression of Vascular Endothelial Growth Factor/Vascular Permeability Factor by Human Lung Cancer Cells. American Journal Of Pathology 2000, 157: 1893-1903. PMID: 11106562, PMCID: PMC1885766, DOI: 10.1016/s0002-9440(10)64828-6.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAnimalsCapillary PermeabilityCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCytokinesEndothelial Growth FactorsHumansLungLung NeoplasmsLymphokinesMatrix MetalloproteinasesMiceMice, NudeNeoplasm InvasivenessNeoplasm TransplantationOligonucleotides, AntisensePleuraPleural EffusionTissue Inhibitor of MetalloproteinasesTransfectionTumor Cells, CulturedUrokinase-Type Plasminogen ActivatorVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsProduction of malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells
Yano S, Herbst R, Sone S, Fidler I. Production of malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Lung Cancer 2000, 29: 217. DOI: 10.1016/s0169-5002(00)80743-6.Peer-Reviewed Original ResearchTreatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, Wood J, Fidler IJ. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clinical Cancer Research 2000, 6: 957-65. PMID: 10741721.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAngiogenesis InhibitorsAnimalsCapillary PermeabilityCell DivisionCell LineEndothelial Growth FactorsEndothelium, VascularGene Expression RegulationHumansImmunohistochemistryIn Situ HybridizationLung NeoplasmsLymphokinesMaleMiceMice, Inbred BALB CMice, NudeNeoplasm TransplantationNeovascularization, PathologicPhosphorylationPhthalazinesPleural Effusion, MalignantPyridinesReceptor Protein-Tyrosine KinasesReceptors, Growth FactorReceptors, Vascular Endothelial Growth FactorTransplantation, HeterologousTumor Cells, CulturedVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsMalignant pleural effusionReceptor tyrosine kinase inhibitorsPleural effusionPTK 787Human dermal microvascular endothelial cellsTyrosine kinase inhibitorsPC14PE6 cellsDermal microvascular endothelial cellsMicrovascular endothelial cellsVEGF/VPFOral treatmentLung lesionsGrowth factor receptor tyrosine kinase inhibitorsAdvanced human lung cancerPlatelet-derived growth factor receptor tyrosine kinase inhibitorVEGF/VPF proteinEndothelial cellsKinase inhibitorsVascular endothelial growth factor/vascular permeability factorHuman lung cancerNude mouse modelHuman lung adenocarcinomaHuman lung adenocarcinoma cellsVascular permeability factorHuman lung carcinoma cells